Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Mar 27;7:431. doi: 10.1038/s41598-017-00275-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Pharmacological isolation of the VGCC current component enhanced by bilirubin. (a) Example traces are shown in control (black traces), during application of 1 µM Mibefradil (top panel, magenta trace, n = 7), 10 µM Nifedipine (2nd panel, green trace, n = 7), 1 µM ω-CTx GVIA (3rd panel, olive trace, n = 7), 50 µM NiCl₂ (4th panel, cyan trace, n = 7), or 500 nM ω- Agatoxin IVA (bottom panel, blue trace, n = 7), respectively, and subsequent application of 6 µM Bilirubin (red traces), elicited by step depolarizations to −10 mV from a hyperpolarizing potential of −100 mV. (b) Current-voltage relationships from data in A measured at the peak current density showed calcium currents in control (black traces), Mibefradil (top panel, magenta trace), Nifedipine (2nd panel, green trace), ω-CTx GVIA (3rd panel, olive trace), NiCl₂ (4th panel, cyan trace), or ω- Agatoxin IVA (bottom panel, blue trace), respectively, and further addition of 6 µM bilirubin (red traces). (c) Time course of the effect of control condition, each antagonist and co-application of bilirubin. The calcium current density is plotted against time. (d) The normalized VGCC current amplitude before (black bars), during application of Mibefradil (top panel, magenta bar), Nifedipine (2nd panel, green bar), ω-CTx GVIA (3rd panel, olive bar), NiCl₂ (4th panel, cyan bar), or ω- Agatoxin IVA (bottom panel, blue bar), respectively, and combined application of 6 μM bilirubin (red bars). Charge carrier: 5 mM Ba²⁺. *P < 0.05, **P < 0.01, ns, not significant, one-way ANOVA with Bonferroni post hoc test.